

after the meeting until close of business on that day.

Persons attending ONC's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

ONC welcomes the attendance of the public at its advisory committee meetings. Seating is limited at the location, and ONC will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact MacKenzie Robertson at least seven (7) days in advance of the meeting.

Notice of this meeting is given under the Federal Advisory Committee Act (Pub. L. No. 92-463, 5 U.S.C., App. 2).

Dated: September 27, 2012.

MacKenzie Robertson,

FACA Program Lead, Office of Policy and Planning, Office of the National Coordinator for Health Information Technology.

[FR Doc. 2012-24386 Filed 10-2-12; 8:45 am]

BILLING CODE 4150-45-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Establishment

Pursuant to the Homeland Security Presidential Directive (HSPD-21); Section 222 of the Public Health Service Act, [42 U.S.C. 217a] as amended, the Director, Centers for Disease Control and Prevention (CDC), announces the

establishment of the National Public Health Surveillance and Biosurveillance Advisory Committee (NPHSAC).

The National Public Health Surveillance and Biosurveillance Advisory Committee shall advise the Secretary, HHS; the Assistant Secretary for Health; the Assistant Secretary for Preparedness and Response; the Director, CDC; and the Director, Office of Surveillance, Epidemiology and Laboratory Services (OSELs) regarding the broad range of issues impacting the human health component of biosurveillance.

For information, contact Pamela Diaz, M.D., Designated Federal Officer, National Public Health Surveillance and Biosurveillance Advisory Committee, OSELs, Public Health Surveillance Program Office, CDC, 1600 Clifton Road, NE., Atlanta, Georgia 30333, telephone (404) 498-0476, or email: pdiaz@cdc.gov.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both the Centers for Disease Control and Prevention, and the Agency for Toxic Substances and Disease Registry.

Dated: September 24, 2012.

Elaine L. Baker,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2012-24423 Filed 10-2-12; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

[CFDA Number 93.093]

Notice of the Award of Single-Source Program Expansion Supplements to Multiple Grantees Under the Health Profession Opportunity Grants (HPOG)

AGENCY: Office of Family Assistance, ACF, HHS.

ACTION: Award of single-source program expansion supplement grants to multiple grantees under the Office of Family Assistance's Health Profession Opportunity Grants program

SUMMARY: This Administration for Children and Families (ACF), Office of Family Assistance (OFA), Health Profession Opportunity Grants (HPOG) program announces the award of single-source program expansion supplements to all grantees under this program.

DATES: The project period for the award is September 30, 2012–September 29, 2013.

FOR FURTHER INFORMATION CONTACT: Stan Koutstaal, Program Manager, Office of Family Assistance, 370 L'Enfant Promenade, SW., Washington, DC 20447. Telephone: 202-401-5457; Email: stanley.koutstaal@acf.hhs.gov.

SUPPLEMENTARY INFORMATION: The following grantees will receive single-source program expansion supplements:

Organization name	Location	State	Supplement award
Bergen Community College	Paramus	NJ	\$125,000
Central Community College	Grand Island	NE	125,000
Office of Minority Health Department of Health and Human Services	Concord	NH	125,000
Eastern Gateway Community College	Steubenville	OH	1,535,534
Pima County Community College District	Tucson	AZ	125,000
Buffalo and Erie County Workforce Development Consortium, Inc	Buffalo	NY	125,000
Schenectady County Community College	Schenectady	NY	125,000
Gateway Community and Technical College	Florence	KY	125,000
Temple University of the Commonwealth System of Higher Ed	Philadelphia	PA	125,000
Community Action Project of Tulsa County, Inc	Tulsa	OK	125,000
Central Susquehanna Intermediate Unit	Lewisburg	PA	876,159
Milwaukee Area Workforce Investment Board, Inc	Milwaukee	WI	125,000
Full Employment Council	Kansas City	MO	125,000
South Carolina Department of Social Services	Columbia	SC	125,000
Will County	Joliet	IL	125,000
District Board of Trustees of Pensacola State College	Pensacola	FL	125,000
Alamo Community College District	San Antonio	TX	125,000
Gateway Technical College	Kenosha	WI	125,000
Workforce Development Council of Seattle-King County	Seattle	WA	125,000
Kansas Department of Commerce	Topeka	KS	125,000
San Diego Workforce Partnership, Inc	San Diego	CA	125,000
Research Foundation of the City University of New York—Hostos Community College	Bronx	NY	125,000
Workforce Investment Board SDA-83, Inc	Monroe	LA	125,000
Edmonds Community College	Lynnwood	WA	125,000
Southland Health Care Forum, Inc.	Chicago Heights	IL	125,000
Suffolk County Department of Labor	Hauppauge	NY	125,000

Organization name	Location	State	Supplement award
The WorkPlace, Inc.	Bridgeport	CT	125,000
Blackfeet Community College	Browning	MT	125,000
Turtle Mountain Community College	Belcourt	ND	125,000
Cook Inlet Tribal Council, Inc.	Anchorage	AK	125,000
College of Menominee Nation	Keshena	WI	125,000
Cankdeska Cikana Community College	Fort Totten	ND	125,000

Statutory Authority: Section 2008(a) of Title XX of the Social Security Act, as amended by Section 5507 of the Affordable Care Act (Pub. L. 111–148).

Earl S. Johnson,

Director, Office of Family Assistance.

[FR Doc. 2012–24310 Filed 10–2–12; 8:45 am]

BILLING CODE 4184–48–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2012–N–0001]

Clinical Investigator Training Course

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research/Office of Medical Policy and the Duke University Office of Continuing Medical Education are cosponsoring a 3-day training course for clinical investigators on scientific, ethical, and regulatory aspects of clinical trials. This training course is intended to provide clinical investigators with expertise in the design, conduct, and analysis of clinical trials; improve the quality of clinical trials; and enhance the safety of trial participants. Senior FDA staff will communicate directly with clinical investigators on issues of greatest importance for successful clinical research.

Date and Time: The training course will be held on November 13 and 14, 2012, from 8 a.m. to 5 p.m., and on November 15, 2012, from 8 a.m. to 4 p.m.

Location: The course will be held at the Holiday Inn College Park, 10000 Baltimore Ave., College Park, MD 20740.

Contact Person: Connie Wisner, Office of Medical Policy, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, rm. 6360, Silver Spring, MD 20993, 301–796–8509.

Registration: Register by October 22, 2012. The registration fee is \$400 per person. The fee includes course materials and onsite lunch. Early registration is recommended because seating is limited. There will be no onsite registration.

Register online for the training course at the registration Web site: http://evm.auxserv.duke.edu/iebms/reg/reg_p1_form.aspx?oc=10&ct=DCRINVEST&eventid=46475 or download a full-size copy of the registration form and mail a check and completed form to: Duke University Conference and Event Services, FDA Investigator Course Box 90841, 101 Bryan Center, Durham, NC 27708. You will receive an email that confirms your registration. (FDA has verified the Web site address, but FDA is not responsible for subsequent changes to the Web site after this document publishes in the **Federal Register**.)

Attendees are responsible for their own accommodations. A block of rooms has been reserved under “FDA Clinical Investigator Course” at the Holiday Inn College Park at a reduced conference rate. Reservations for these accommodations can be made online using the course registration Web site mentioned previously. Click on “registration form.” You will see a direct link to the hotel.

Registration materials, payment procedures, accommodation information, and a detailed description of the course can be found at the registration/information Web site mentioned previously.

If you need special accommodations due to a disability, please contact Connie Wisner at least 7 days in advance. Persons attending the course are advised that FDA is not responsible for providing access to electrical outlets.

I. Background

Clinical trial investigators play a critical role in the development of medical products. They are responsible for ensuring the safe and ethical treatment of study subjects and for collecting adequate and reliable data to support regulatory decisions. This course is intended to assist clinical investigators in understanding what

preclinical and clinical information is needed to support the investigational use of medical products, as well as the scientific, regulatory, and ethical considerations involved in the conduct of clinical trials. The course will cover a wide variety of key topics, including material on novel safety concerns, adverse event monitoring, compliance with the legal and ethical obligations of clinical research, and acceptable scientific and analytic standards in the design and conduct of clinical studies. The faculty will include a diverse representation of senior FDA staff, enabling FDA to communicate directly with clinical investigators on issues of greatest importance for successful clinical research.

II. Description of the Training Course

A. Purpose

The training course is designed to provide clinical investigators with an overview of the following information:

- The essential toxicological, pharmacological, and manufacturing data to support investigational drug use in humans;
- Fundamental issues in the design and conduct of clinical trials;
- Statistical and analytic considerations in the interpretation of trial data;
- Appropriate safety evaluation during studies; and
- The ethical considerations and regulatory requirements for clinical trials.

In addition, the course should do the following:

- Foster a cadre of clinical investigators with knowledge, experience, and commitment to investigational medicine;
- Promote communication between clinical investigators and FDA;
- Enhance investigators’ understanding of FDA’s role in experimental medicine; and
- Improve the quality of data while enhancing subject protection in the performance of clinical trials.

B. Proposed Agenda

The course will be conducted over 3 days and comprised of approximately 26 lectures, each lasting between 30 and